Concepts (272)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Critical Care | 20 | 2022 | 650 | 4.610 |
Why?
|
| Heart Defects, Congenital | 26 | 2022 | 1813 | 3.680 |
Why?
|
| Cardiopulmonary Bypass | 14 | 2021 | 344 | 3.460 |
Why?
|
| Cardiac Surgical Procedures | 17 | 2024 | 1103 | 2.500 |
Why?
|
| Pediatrics | 12 | 2022 | 1158 | 2.380 |
Why?
|
| Hemodynamics | 14 | 2023 | 847 | 2.180 |
Why?
|
| Critical Illness | 11 | 2023 | 598 | 2.150 |
Why?
|
| Monitoring, Physiologic | 11 | 2022 | 366 | 1.820 |
Why?
|
| Oxygen | 8 | 2021 | 552 | 1.690 |
Why?
|
| Intensive Care Units, Pediatric | 9 | 2021 | 477 | 1.560 |
Why?
|
| Shock, Cardiogenic | 2 | 2023 | 191 | 1.530 |
Why?
|
| Cardiology | 4 | 2017 | 476 | 1.530 |
Why?
|
| Oximetry | 7 | 2021 | 162 | 1.410 |
Why?
|
| Heart Failure | 8 | 2016 | 2157 | 1.390 |
Why?
|
| Spectroscopy, Near-Infrared | 4 | 2021 | 134 | 1.380 |
Why?
|
| Capnography | 2 | 2020 | 13 | 1.280 |
Why?
|
| Cardiovascular System | 2 | 2023 | 102 | 1.280 |
Why?
|
| Heart Diseases | 4 | 2019 | 484 | 1.230 |
Why?
|
| Sepsis | 2 | 2023 | 478 | 1.220 |
Why?
|
| Child | 46 | 2022 | 24478 | 1.030 |
Why?
|
| Nitric Oxide | 5 | 2019 | 449 | 1.010 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2017 | 276 | 0.970 |
Why?
|
| Cardiac Output | 7 | 2022 | 170 | 0.940 |
Why?
|
| Physicians | 3 | 2022 | 584 | 0.920 |
Why?
|
| Humans | 84 | 2024 | 124270 | 0.910 |
Why?
|
| Arginine Vasopressin | 1 | 2023 | 28 | 0.870 |
Why?
|
| Heart | 4 | 2023 | 724 | 0.850 |
Why?
|
| Blood Pressure | 6 | 2022 | 1329 | 0.810 |
Why?
|
| Extracorporeal Membrane Oxygenation | 6 | 2014 | 628 | 0.800 |
Why?
|
| Hypertension, Pulmonary | 5 | 2019 | 434 | 0.780 |
Why?
|
| Cerebrovascular Circulation | 3 | 2021 | 431 | 0.770 |
Why?
|
| Certification | 2 | 2019 | 67 | 0.760 |
Why?
|
| Tetralogy of Fallot | 3 | 2012 | 163 | 0.760 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2021 | 152 | 0.750 |
Why?
|
| Inflammation | 2 | 2020 | 1414 | 0.750 |
Why?
|
| Postoperative Complications | 8 | 2020 | 3048 | 0.740 |
Why?
|
| Lung | 2 | 2020 | 1485 | 0.740 |
Why?
|
| Fontan Procedure | 1 | 2023 | 187 | 0.730 |
Why?
|
| Heart-Assist Devices | 3 | 2022 | 1045 | 0.710 |
Why?
|
| Acute Kidney Injury | 3 | 2017 | 624 | 0.700 |
Why?
|
| Natriuretic Agents | 2 | 2017 | 32 | 0.690 |
Why?
|
| Infant, Newborn | 17 | 2022 | 8180 | 0.680 |
Why?
|
| Infant | 24 | 2020 | 12463 | 0.650 |
Why?
|
| Triiodothyronine | 1 | 2019 | 64 | 0.640 |
Why?
|
| Internationality | 1 | 2019 | 129 | 0.630 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 316 | 0.610 |
Why?
|
| Education, Medical, Graduate | 2 | 2022 | 511 | 0.610 |
Why?
|
| Postoperative Care | 5 | 2020 | 295 | 0.600 |
Why?
|
| Respiratory Tract Diseases | 2 | 2016 | 75 | 0.600 |
Why?
|
| Hypothyroidism | 1 | 2019 | 93 | 0.590 |
Why?
|
| Curriculum | 2 | 2022 | 723 | 0.590 |
Why?
|
| Hospital Mortality | 5 | 2021 | 1016 | 0.570 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 2885 | 0.550 |
Why?
|
| Vasopressins | 3 | 2021 | 43 | 0.550 |
Why?
|
| Carbon Dioxide | 2 | 2020 | 273 | 0.550 |
Why?
|
| Hormone Replacement Therapy | 1 | 2019 | 198 | 0.540 |
Why?
|
| Immunomodulation | 1 | 2016 | 81 | 0.520 |
Why?
|
| Respiratory System | 1 | 2016 | 95 | 0.510 |
Why?
|
| Reperfusion Injury | 1 | 2016 | 103 | 0.500 |
Why?
|
| Societies, Medical | 5 | 2015 | 681 | 0.500 |
Why?
|
| Shock | 1 | 2016 | 90 | 0.490 |
Why?
|
| Clinical Competence | 2 | 2019 | 991 | 0.490 |
Why?
|
| Immune System Diseases | 1 | 2015 | 46 | 0.490 |
Why?
|
| Child, Preschool | 18 | 2020 | 14052 | 0.480 |
Why?
|
| Congresses as Topic | 1 | 2015 | 172 | 0.460 |
Why?
|
| Child Abuse | 1 | 2017 | 195 | 0.450 |
Why?
|
| Education, Medical | 1 | 2017 | 289 | 0.440 |
Why?
|
| Fellowships and Scholarships | 1 | 2016 | 274 | 0.440 |
Why?
|
| Shock, Septic | 1 | 2015 | 146 | 0.440 |
Why?
|
| Ventilator Weaning | 2 | 2010 | 23 | 0.430 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2013 | 43 | 0.430 |
Why?
|
| Cardiovascular Diseases | 3 | 2016 | 1887 | 0.420 |
Why?
|
| Oxygen Consumption | 2 | 2011 | 307 | 0.410 |
Why?
|
| Vascular Resistance | 2 | 2020 | 189 | 0.410 |
Why?
|
| Vancomycin | 1 | 2014 | 218 | 0.400 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 213 | 0.390 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2011 | 15 | 0.380 |
Why?
|
| Length of Stay | 6 | 2021 | 1306 | 0.380 |
Why?
|
| Airway Extubation | 1 | 2012 | 67 | 0.380 |
Why?
|
| Consensus | 2 | 2011 | 628 | 0.360 |
Why?
|
| Positive-Pressure Respiration | 1 | 2010 | 82 | 0.350 |
Why?
|
| Cardiac Output, Low | 1 | 2010 | 67 | 0.350 |
Why?
|
| Intensive Care Units | 6 | 2020 | 484 | 0.340 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 134 | 0.340 |
Why?
|
| Pituitary-Adrenal System | 1 | 2010 | 36 | 0.340 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2010 | 65 | 0.330 |
Why?
|
| Brain | 2 | 2012 | 3000 | 0.330 |
Why?
|
| Adrenal Insufficiency | 1 | 2010 | 29 | 0.330 |
Why?
|
| Retrospective Studies | 15 | 2022 | 16214 | 0.330 |
Why?
|
| Treatment Outcome | 12 | 2024 | 12264 | 0.320 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2010 | 79 | 0.320 |
Why?
|
| Coronary Care Units | 4 | 2020 | 36 | 0.310 |
Why?
|
| Respiration, Artificial | 6 | 2019 | 459 | 0.310 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 625 | 0.310 |
Why?
|
| Postoperative Period | 4 | 2019 | 333 | 0.300 |
Why?
|
| Diuretics | 3 | 2019 | 159 | 0.300 |
Why?
|
| Steroids | 1 | 2009 | 203 | 0.290 |
Why?
|
| Infusions, Intravenous | 3 | 2020 | 548 | 0.290 |
Why?
|
| Peritoneal Dialysis | 2 | 2020 | 119 | 0.290 |
Why?
|
| Arteries | 2 | 2019 | 222 | 0.280 |
Why?
|
| Hospitalization | 5 | 2021 | 1752 | 0.270 |
Why?
|
| Fluid Therapy | 2 | 2022 | 126 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 1096 | 0.270 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2021 | 147 | 0.260 |
Why?
|
| Dexamethasone | 3 | 2005 | 276 | 0.260 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2024 | 281 | 0.250 |
Why?
|
| Administration, Inhalation | 3 | 2019 | 180 | 0.250 |
Why?
|
| Prospective Studies | 7 | 2020 | 6087 | 0.240 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2009 | 314 | 0.240 |
Why?
|
| Respiration | 3 | 2016 | 122 | 0.240 |
Why?
|
| Male | 22 | 2020 | 60887 | 0.230 |
Why?
|
| Creatinine | 2 | 2017 | 382 | 0.220 |
Why?
|
| Acute Disease | 3 | 2016 | 1098 | 0.220 |
Why?
|
| Heart Rate | 3 | 2020 | 590 | 0.220 |
Why?
|
| Female | 22 | 2020 | 66294 | 0.220 |
Why?
|
| Cause of Death | 2 | 2019 | 466 | 0.220 |
Why?
|
| Mediastinum | 1 | 2023 | 41 | 0.220 |
Why?
|
| Time Factors | 6 | 2019 | 6252 | 0.210 |
Why?
|
| Hemodynamic Monitoring | 1 | 2022 | 12 | 0.210 |
Why?
|
| Cooperative Behavior | 2 | 2016 | 220 | 0.200 |
Why?
|
| Water | 1 | 2023 | 185 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 2414 | 0.200 |
Why?
|
| Pain, Postoperative | 1 | 2024 | 259 | 0.190 |
Why?
|
| Vena Cava, Superior | 1 | 2021 | 56 | 0.180 |
Why?
|
| Case-Control Studies | 3 | 2019 | 3261 | 0.180 |
Why?
|
| Biological Transport | 2 | 2011 | 346 | 0.180 |
Why?
|
| United States | 6 | 2022 | 10756 | 0.180 |
Why?
|
| Age Factors | 2 | 2019 | 2812 | 0.170 |
Why?
|
| Tidal Volume | 1 | 2020 | 39 | 0.170 |
Why?
|
| Nicardipine | 1 | 2020 | 18 | 0.170 |
Why?
|
| Nitroprusside | 1 | 2020 | 46 | 0.170 |
Why?
|
| Sodium Bicarbonate | 1 | 2020 | 52 | 0.170 |
Why?
|
| Hypotension | 1 | 2021 | 180 | 0.170 |
Why?
|
| Vasoconstrictor Agents | 1 | 2020 | 137 | 0.170 |
Why?
|
| Cardiomyopathies | 2 | 2020 | 480 | 0.170 |
Why?
|
| Risk Assessment | 5 | 2021 | 3367 | 0.170 |
Why?
|
| Heart Septal Defects | 1 | 2019 | 40 | 0.160 |
Why?
|
| Acidosis | 1 | 2020 | 94 | 0.160 |
Why?
|
| Noonan Syndrome | 1 | 2019 | 30 | 0.160 |
Why?
|
| Arginine | 1 | 2021 | 332 | 0.160 |
Why?
|
| Heart Valve Diseases | 1 | 2019 | 167 | 0.150 |
Why?
|
| Bronchodilator Agents | 1 | 2019 | 153 | 0.150 |
Why?
|
| Respiratory Insufficiency | 2 | 2012 | 231 | 0.150 |
Why?
|
| Oliguria | 1 | 2017 | 19 | 0.140 |
Why?
|
| Nurses | 1 | 2017 | 64 | 0.140 |
Why?
|
| Water-Electrolyte Balance | 1 | 2017 | 80 | 0.140 |
Why?
|
| Chlorothiazide | 1 | 2016 | 12 | 0.140 |
Why?
|
| Nephrons | 1 | 2016 | 20 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2019 | 440 | 0.140 |
Why?
|
| Diuresis | 1 | 2016 | 58 | 0.130 |
Why?
|
| Veins | 1 | 2017 | 107 | 0.130 |
Why?
|
| Adolescent | 6 | 2021 | 19308 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 1688 | 0.130 |
Why?
|
| Reoperation | 1 | 2019 | 822 | 0.130 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 39 | 0.130 |
Why?
|
| Risk Factors | 4 | 2020 | 10121 | 0.130 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2015 | 10 | 0.130 |
Why?
|
| Ventricular Pressure | 1 | 2016 | 43 | 0.130 |
Why?
|
| Inpatients | 1 | 2020 | 495 | 0.130 |
Why?
|
| Specialization | 1 | 2016 | 76 | 0.130 |
Why?
|
| Alprostadil | 1 | 2015 | 27 | 0.130 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 725 | 0.120 |
Why?
|
| Survival Analysis | 3 | 2019 | 1478 | 0.120 |
Why?
|
| Weight Gain | 1 | 2017 | 405 | 0.120 |
Why?
|
| Educational Measurement | 1 | 2017 | 324 | 0.120 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2016 | 122 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2019 | 768 | 0.120 |
Why?
|
| Premedication | 2 | 2005 | 43 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5094 | 0.110 |
Why?
|
| Single-Blind Method | 1 | 2014 | 236 | 0.110 |
Why?
|
| Vasodilator Agents | 1 | 2015 | 204 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1415 | 0.110 |
Why?
|
| Cardiotonic Agents | 2 | 2014 | 135 | 0.110 |
Why?
|
| Pregnancy Complications | 2 | 2017 | 507 | 0.110 |
Why?
|
| Publications | 1 | 2013 | 33 | 0.110 |
Why?
|
| Global Health | 1 | 2017 | 555 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1088 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 586 | 0.100 |
Why?
|
| Databases, Factual | 3 | 2020 | 1174 | 0.100 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 1 | 2012 | 5 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 233 | 0.100 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 198 | 0.100 |
Why?
|
| Thrombolytic Therapy | 1 | 2014 | 204 | 0.100 |
Why?
|
| Logistic Models | 2 | 2014 | 1801 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2016 | 546 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2016 | 383 | 0.100 |
Why?
|
| Animals | 4 | 2024 | 34158 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 176 | 0.090 |
Why?
|
| Texas | 3 | 2015 | 3586 | 0.090 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2014 | 256 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2016 | 1183 | 0.090 |
Why?
|
| Hypertension | 1 | 2020 | 1286 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 3412 | 0.090 |
Why?
|
| Quality Control | 1 | 2011 | 119 | 0.090 |
Why?
|
| Calcium | 1 | 2016 | 1101 | 0.090 |
Why?
|
| California | 1 | 2010 | 128 | 0.090 |
Why?
|
| Registries | 2 | 2019 | 1411 | 0.090 |
Why?
|
| Respiratory Mechanics | 1 | 2010 | 75 | 0.090 |
Why?
|
| Kidney | 1 | 2017 | 1346 | 0.080 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 86 | 0.080 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2009 | 31 | 0.080 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 783 | 0.080 |
Why?
|
| Reperfusion | 1 | 2009 | 25 | 0.080 |
Why?
|
| Pressure | 1 | 2009 | 129 | 0.080 |
Why?
|
| Biomarkers | 2 | 2014 | 2974 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 78 | 0.070 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2009 | 173 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 209 | 0.070 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2010 | 361 | 0.070 |
Why?
|
| Incidence | 1 | 2014 | 3078 | 0.070 |
Why?
|
| Obesity | 1 | 2017 | 2253 | 0.070 |
Why?
|
| Methylprednisolone | 1 | 2005 | 90 | 0.060 |
Why?
|
| Linear Models | 2 | 2017 | 671 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1241 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 1266 | 0.060 |
Why?
|
| Cannabinoids | 1 | 2024 | 31 | 0.060 |
Why?
|
| Cytokines | 1 | 2009 | 1273 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2005 | 384 | 0.050 |
Why?
|
| Central Venous Pressure | 1 | 2022 | 25 | 0.050 |
Why?
|
| Troponin I | 1 | 2003 | 96 | 0.050 |
Why?
|
| Prognosis | 1 | 2011 | 4548 | 0.050 |
Why?
|
| Phentolamine | 1 | 2021 | 20 | 0.050 |
Why?
|
| Calcium Chloride | 1 | 2021 | 22 | 0.050 |
Why?
|
| Morbidity | 2 | 2015 | 243 | 0.050 |
Why?
|
| Japan | 1 | 2020 | 133 | 0.040 |
Why?
|
| Complement C3a | 1 | 2000 | 19 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2020 | 147 | 0.040 |
Why?
|
| Medical Staff, Hospital | 1 | 2020 | 92 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2003 | 1614 | 0.040 |
Why?
|
| Body Temperature | 1 | 2000 | 113 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2000 | 247 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2020 | 426 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2020 | 103 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 210 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2000 | 414 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2020 | 449 | 0.040 |
Why?
|
| Neutrophils | 1 | 2000 | 378 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2017 | 57 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2000 | 670 | 0.040 |
Why?
|
| Furosemide | 1 | 2016 | 37 | 0.030 |
Why?
|
| Down Syndrome | 1 | 2019 | 195 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 254 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 440 | 0.030 |
Why?
|
| Birthing Centers | 1 | 2015 | 10 | 0.030 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2017 | 230 | 0.030 |
Why?
|
| Bradycardia | 1 | 2014 | 59 | 0.030 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2013 | 16 | 0.030 |
Why?
|
| Pregnancy | 2 | 2017 | 7248 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 1154 | 0.030 |
Why?
|
| Gases | 1 | 2012 | 15 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 235 | 0.030 |
Why?
|
| Missouri | 1 | 2012 | 36 | 0.030 |
Why?
|
| Adult | 3 | 2020 | 29357 | 0.030 |
Why?
|
| Troponin | 1 | 2012 | 72 | 0.030 |
Why?
|
| Catheterization | 1 | 2014 | 238 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 2014 | 193 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 676 | 0.020 |
Why?
|
| Radiography | 1 | 2014 | 823 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2017 | 1554 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2014 | 376 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 1423 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2014 | 950 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2014 | 581 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1396 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 2037 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2005 | 286 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 8954 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2005 | 197 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 424 | 0.010 |
Why?
|
| Aged | 1 | 2020 | 19386 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 1014 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 26367 | 0.010 |
Why?
|